Beth Wallace, MD, MS

Although use of corticosteroid premedication prior to infliximab infusions is declining, it remains unnecessarily high despite limited benefit and the risk of serious adverse events from corticosteroids.

Thirty-day readmissions related to inflammatory bowel disease are common and associated with longer length of stay and a higher likelihood of having an associated comorbid condition compared with index hospitalizations.